• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Publications and Presentations for Laboratory of Toxicology and Biocompatibility

Biocompatibility and risk assessment

  • Gillum N, Karabekian Z, Swift LM, Brown RP, Kay MW, Sarvazyan N.  Clinically relevant concentrations of di(2-ethylhexyl) phthalate (DEHP) uncouple cardiac syncytium.  Toxicol Appl Pharmacol. 236:25-38, 2009. 

 

Preclinical biomarkers of tissue injury 

  • Espandiari P, Rosenzweig B, Zhang J, Zhou Y, Schnackenberg L, Vaidya VS, Goering PL, Brown RP,  Bonventre JV, Mahjoob K, Holland R, Beger RD, Thompson K, Hanig J and Sadrieh N.  Age-related differences in susceptibility to cisplatin induced renal toxicity.  J. Appl. Toxicol. 30:172-182, 2010. 
  • Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD and Bonventre JV.  Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.  Nature Biotechnol. 28:478-485, 2010. 
  • Sistare FD, Dieterle F, Troth S, ..., Goering PL et al.  Towards consensus practices to qualify safety biomarkers for use in early drug development.  Nature Biotechnol. 28:446-454, 2010. 
  • Dieterle F, Sistare F, Goodsaid F, …, Goering PL et al.  Renal biomarker qualification submission:  a dialog between the FDA-EMEA and Predictive Safety Testing Consortium.  Nature Biotechnol. 28:455-462, 2010. 
  • Zhang J, Goering PL, Espandiari P, Shaw M, Bonventre JV, Vaidya VS, Brown RP, Keenan J, Kilty CG, Sadrieh N and Hanig JP.  Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney between gentamicin- and cisplatin-, and valproic acid-treated rats: Role of iNOS and nitrotyrosine.  Toxicol. Pathology 37:629-643, 2009. 
  • Zhou Y, Vaidya VS, Brown RP, Rosenzweig BA, Johnson AM, Thompson KL, Zhang J,  Miller T, Bonventre JV and Goering PL.  Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney after acute exposure to gentamicin, mercury, and chromium.  Toxicol. Sciences 101(1):159-170, 2008. 
  • Zhang J, Brown RP, Shaw M, Vaidya VS, Zhou Y, Espandiari P, Sadrieh N, Keenan J, Stratmeyer M, Kilty CG, Bonventre JV and Goering PL.  Immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney of gentamicin-, mercury-, or chromium-treated rats: Relation to renal distribution of iNOS and nitrotyrosine.  Toxicol. Pathology 36:397-409, 2008. 
  • Zhang J, Shaw M, and Goering PL.  Renal papillary antigen-1 (RPA-1) cross-reactivity in necrotic renal proximal tubules: Significance of immunohistochemistry and histopathology. Toxicol. Pathology 36:891-893, 2008. 
  • Papaconstantinou AD, Brown KM, Fisher BR, Noren BT, McAllister T and Goering PL.  Mercury, cadmium, and arsenite enhance heat shock protein synthesis in chick embryos prior to embryotoxicity.  Birth Defects Research (Part B- Developmental and Reproductive Toxicology) 68:456-464, 2003. 

 

Nanotechnology

  • Zhang Q, Hitchins VM, Schrand A, Hussain S, and Goering PL.  Uptake of gold nanoparticles in murine macrophage cells without cytotoxicity or production of pro-inflammatory mediators.  Nanotoxicology (accepted for publication - May 2010). 
  • Patri AK, Umbreit TH, Zheng J, Nagashima K, Goering PL, Francke-Carroll S, Weaver JL, Miller TJ, Sadrieh N, McNeil SE and Stratmeyer ME.  Energy dispersive X-ray analysis of titanium dioxide nanoparticle distribution after intravenous and subcutaneous injection in mice.  J. Appl. Toxicol. 29:662-672, 2009. 
  • Choi J, Zhang Q, Reipa V, Wang NS, Stratmeyer ME, Hitchins VM, and Goering PL.  Comparison of cytotoxic and inflammatory responses of photoluminescent silicon nanoparticles with silicon micron-sized particles in RAW 264.7 macrophages.  J. Appl. Toxicol. 29:52-60, 2009. 
  • Stratmeyer, ME, Goering PL, Hitchins VM and Umbreit TH.  What we know and don’t know about the bioeffects of nanoparticles: Developing experimental approaches for safety assessment.   Biomedical Microdevices (Epub ahead of print) Dec 4, 2008. 
  • Balbus J, Maynard A, Colvin V, Castranova V, Daston G, Denison R, Dreher K, Goering P, Goldberg A, Kulinowski K, Monteiro-Riviere N, Oberdörster G, Omenn G, Pinkerton K, Ramos K, Sass J, and Silbergeld E.  Hazard Assessment for Nanoparticles: Report from an Interdisciplinary Workshop.  Environmental Health Perspectives 115(11):1654-1659, 2007.